![FDA, NCI align to simplify clinical research, producing a model “pragmatic” registration trial in NSCLC](https://cdn.cancerletter.com/media/2022/12/02143405/48-43-lungs-4x3-1.jpg)
![FDA, NCI align to simplify clinical research, producing a model “pragmatic” registration trial in NSCLC](https://cdn.cancerletter.com/media/2022/12/02143405/48-43-lungs-4x3-1.jpg)
Cover Story
Clinical
Pragmatica-Lung is shaping up as the clinical trial to watch—not just because of the research question, but because of the way it’s being addressed.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
Drugs & Targets
NCI Trials
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
NCI Trials for December 2022
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- Better oncology drug management could lead to improved outcomes, lower costs
- Tweaking the existing systems is not the answer to drug shortages